{
    "clinical_study": {
        "@rank": "1667", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1: PF-06372865 10 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 2: PF-06372865 TBD dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cohort 3: PF-06372865 TBD dose", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will see how PF-06372865, an experimental drug distributes in the brain after one\n      dose of PF-06372865 is administered orally to healthy volunteer subjects. The study will\n      also evaluate the safety and tolerability of PF-06372865in these subjects and will measure\n      the level of PF-06372865 in the blood."
        }, 
        "brief_title": "A Study to Examine the Distribution of PF-05212377 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects and female subjects of non-childbearing potential between the\n             ages of 18 and 55 years, inclusive.\n\n          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110\n             lbs).\n\n          -  Subjects who are willing and able to comply with all scheduled visits, treatment\n             plan, laboratory tests, and other study procedures.\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated, asymptomatic,\n             seasonal allergies at the time of dosing).\n\n          -  Any condition possibly affecting drug absorption (eg, gastrectomy).\n\n          -  Known or suspected sensitivity to flumazenil and other benzodiazepines."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02138500", 
            "org_study_id": "B7431004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cohort 1: PF-06372865 10 mg", 
                "description": "Single, oral dose administration of 10 mg PF-06372865 using  tablet formulation.", 
                "intervention_name": "PF-06372865", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 2: PF-06372865 TBD dose", 
                "description": "Single, oral dose administration of TBD dose PF-06372865 using  tablet/extemprep formulation.", 
                "intervention_name": "PF-06372865", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cohort 3: PF-06372865 TBD dose", 
                "description": "Single, oral dose administration of TBD dose PF-06372865 using  tablet/extemprep formulation.", 
                "intervention_name": "PF-06372865", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "PF-06372865", 
            "phase 1", 
            "open-label", 
            "GABA-A receptor occupancy", 
            "positron emission tomography", 
            "healthy subjects"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7431004&StudyName=A%20Study%20to%20Examine%20the%20Distribution%20of%20PF-05212377%20in%20the%20Brain%20of%20Healthy%20Volunteers%20Using%20Positron%20Emission%20Tomography%20and%20a%20Radioac"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06511"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06519"
                    }, 
                    "name": "Pfizer Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1, Open-Label Study To Evaluate Central Occupancy Of The Benzodiazepine Binding Site Of Gaba-A Receptors By Positron Emission Tomography (Pet) With Ligand [11c]Flumazenil Following Single Dose Of PF-06372865 In Healthy Subjects", 
        "overall_contact": {
            "last_name": "Pfizer CT.gov Call Center", 
            "phone": "1-800-718-1021"
        }, 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "GABAA RO in the whole brain", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline to days 1 and 2"
            }, 
            {
                "measure": "Average plasma concentration of PF-06372865 in post-dose PET scans after single oral doses of PF-06372865", 
                "safety_issue": "Yes", 
                "time_frame": "Change from baseline to  days 1 and 2"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02138500"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}